Peptide-drug conjugates (PDCs) are the peptide analog of antibody-drug conjugates — a tumor-targeting peptide linked to a cytotoxic payload. The platform sits at the intersection of medicinal chemistry, peptide stability work, and ADC-style delivery.
Lead programs covered on this site: Bicycle Therapeutics' bicyclic peptide-toxin conjugates (BT5528 against EphA2, BT8009 against Nectin-4), Avacta's pre|CISION platform (AVA6103 with exatecan), Lirum's LX-101 against IGF-1R for Ewing sarcoma, and the broader academic peptide-payload work covered at AACR and ASCO. Several have followed ADC-style linker chemistry while keeping the peptide targeting moiety.
Stories here cover trial readouts, partnership deals, and the chemistry papers behind the platform. See #peptide-drug-conjugates for the alternate tag and #bicycle-therapeutics for the leading company.
Indena and Chemi S.p.A. (Italfarmaco Group) announced a strategic partnership in June 2026 combining peptide chemistry and high-potency API (HPAPI) conjugation expertise to position both firms as development and manufacturing partners for biotech and pharmaceutical companies pursuing peptide-drug conjugates (PDCs). Under the agreement, Chemi supplies the peptide carrier molecules and Indena handles the conjugation with highly potent payload molecules. Neither company is developing proprietary PDC drugs; the partnership reflects the broader CDMO consolidation pattern as the PDC modality scales (six PDCs in Phase 3 trials and ~96 in development globally per the April 2026 ResearchAndMarkets report, with Lutathera as the only FDA-approved standalone PDC after Pepaxto's withdrawal and the Pepaxti EMA expansion application pending). The partnership lands alongside CordenPharma's AmbioPharm acquisition and the broader sector reshaping.
MultiValent Biotherapies announced June 16 a first closing of $27.425 million in Series A financing to advance MVB-101, a PSMA × folate-receptor-alpha (FRα) dual-target peptide-drug conjugate licensed from China-based Coherent Biopharma (originally CBP-1018). MVB-101 binds two validated prostate-cancer targets simultaneously; existing PDCs and radioligand therapies (Pluvicto, Lutathera) hit one target each. MultiValent holds exclusive global rights outside greater China. A Phase 1b/2a clinical trial in a subgroup of prostate cancer patients is planned to start in Q3 2026. The launch adds another oncology PDC to a field still dominated by Pluvicto (lutetium-177 PSMA-617), Lutathera, and Pfizer's AVA6000 FAP-Dox.
Cybrexa Therapeutics' CBX-12, a 26-amino-acid pH-targeted peptide-drug conjugate that delivers a topoisomerase-1 inhibitor selectively to the acidic tumor microenvironment, completed Phase 1 in September 2024 and has moved into Phase 2 for platinum-resistant ovarian cancer. The peptide-drug conjugate field continues to broaden beyond the bicyclic-peptide and FAP-activated approaches already covered at ASCO, with smaller direct-acting peptide carriers gaining traction.
The ASCO Annual Meeting closed June 2 after a week that moved peptide and targeted-conjugate oncology from abstract to podium: Bicycle's bicyclic peptide-drug conjugate and Avacta's FAP-activated conjugate in solid tumors, Mayo's folate-receptor and BioVaxys' survivin peptide vaccines, Sapience's C/EBPβ antagonist in glioblastoma, and PSMA and lead-212 radioligands from Telix and Perspective. Attention now shifts to ADA 2026 in New Orleans and the July 23-24 PCAC compounding vote.
On June 1 Avacta reported updated Phase 1a/1b data for faridoxorubicin (AVA6000), a pre|CISION-enabled, FAP-activated doxorubicin peptide-drug conjugate that releases its payload inside the tumor microenvironment. At the recommended expansion dose of 310 mg/m², nearly three times conventional doxorubicin's 75 mg/m² maximum tolerated dose, toxicity stayed below historical doxorubicin rates, and the salivary gland cancer cohort held multiple confirmed responses: four partial and nine minor responses among 38 evaluable patients.
Avacta's AVA6000 — a fibroblast activation protein (FAP)-activated peptide-drug conjugate releasing doxorubicin selectively in the tumor microenvironment — released Phase 1a/1b data at ASCO 2026 in salivary gland cancers. Of 30 patients in the Phase 1b cohort treated at 250 mg/m² and above, two experienced confirmed partial responses (>30% tumor shrinkage) and seven experienced minor responses (10-30% shrinkage). The combined Phase 1a + 1b disease control rate reached 90%. Phase 1a data in 11 patients at the same dose range showed 1 confirmed partial response, 4 minor responses, 1 progression, and 5 stable disease — a 91% disease control rate. The favorable safety profile continued versus conventional doxorubicin, with no severe cardiac toxicity events. The data anchors Avacta's planned Phase 2/3 expansion in adenoid cystic carcinoma — the most common salivary gland cancer subtype, with no FDA-approved systemic therapy.
Avacta Therapeutics reported unaudited preliminary results for the 12 months ended December 31, 2025 on Tuesday May 19, 2026, and disclosed that the first patient received treatment in FOCUS-01 — the Phase 1 clinical trial of AVA6103, a FAP-activated exatecan peptide-drug conjugate — in March 2026. AVA6103 is the second pre|CISION-enabled candidate in the Avacta clinical pipeline, after AVA6000 (FAP-Dox, which has Phase Ia/Ib data scheduled at ASCO 2026 in salivary gland cancers). The pre|CISION platform attaches a peptide tetrazolyl moiety cleaved by FAP (fibroblast activation protein) overexpressed in cancer-associated fibroblasts, allowing systemic administration of cytotoxic payloads without the dose-limiting toxicity that constrains free exatecan. FOCUS-01 is enrolling adults with advanced solid tumors. AVA6103 expands the platform from doxorubicin (in AVA6000) to exatecan — a topoisomerase I inhibitor with potency advantages in HER2-low and triple-negative breast cancer.
A Nature Communications paper published May 13, 2026 reported that chiral engineering of tripeptide-drug conjugates (PDCs) — systematically varying the L/D amino-acid configuration in the peptide moiety — controls phase behavior between liquid-liquid phase separation (LLPS) and β-sheet-rich hydrogel formation. PDCs with alternating L/D residues underwent LLPS in solution; all-L or all-D PDCs formed structured hydrogels. The chirality-controlled phase behavior is a design lever for PDC drug-product engineering: LLPS-prone conjugates dissolve readily for parenteral dosing, while hydrogel-forming variants enable sustained-release depots or injection-site retention. The work expands the design space for peptide-drug conjugate formulation, joining the broader May 2026 PDC research cycle alongside the Avacta AVA6103 FOCUS-01 trial start and the Bicycle Therapeutics ASCO Duravelo-2 readout.
A Molecular Therapy Oncology 2026 paper from a multi-institution collaboration reported that a peptide engineered against Fibulin-4 — a glycoprotein overexpressed in metastatic breast cancer extracellular matrix — successfully targeted and killed metastatic breast cancer cells in mice. The same peptide doubles as an imaging probe, supporting peptide-based detection alongside therapy. The Fibulin-4 target is significant because metastatic breast cancer remains the leading cause of breast cancer mortality and current targeted therapies (HER2, hormone-receptor) leave a substantial therapy gap for triple-negative metastatic disease. The work joins the broader peptide-drug-conjugate field in which six PDCs are in Phase 3 trials and roughly 96 are in development, even as only Lutathera holds active FDA approval after the 2024 Pepaxto withdrawal.
Oncopeptides AB announced May 11-12 it intends to submit a Type II variation application to the European Medicines Agency to expand the Pepaxti (melflufen) label to include third-line treatment of relapsed/refractory multiple myeloma. Pepaxti is one of two FDA-approved peptide-drug conjugates currently on market (the other being Novartis's 177Lu-dotatate Lutathera) and acts as a melphalan-flufenamide alkylating peptide that exploits aminopeptidase enzymes overexpressed in myeloma plasma cells to selectively release the cytotoxic payload inside tumor cells. The Pepaxti EMA label currently covers heavily pre-treated (≥4 prior lines) RRMM; the new third-line expansion submission would meaningfully extend the eligible population. The filing positions the PDC modality for a broader regulatory footprint as the broader peptide-drug-conjugate field heads into ASCO 2026.
Avacta Therapeutics's AVA6000, a fibroblast activation protein (FAP)-activated peptide-drug conjugate releasing doxorubicin selectively in the tumor microenvironment, will be presented at ASCO 2026 (Chicago, May 29-June 2) covering Phase Ia/Ib data in FAP-positive solid tumors with activity against salivary gland cancers — a rare cancer subset with no approved targeted therapies. The pre|CISION platform attaches a peptide tetrazolyl moiety that is cleaved by FAP, an enzyme overexpressed in cancer-associated fibroblasts and selectively present in the tumor stroma, allowing systemic dosing without the cardiotoxicity that limits free doxorubicin. AVA6000 joins Bicycle's nuzefatide pevedotin and Lilly's CRN09682 in the broader peptide-drug conjugate Phase 2/3 cohort.
ResearchAndMarkets published an April 21 PDC market landscape report counting six peptide-drug conjugates currently in Phase III trials and approximately 96 in development across the global pipeline. Lutathera remains the only FDA-approved PDC after Pepaxto's withdrawal, though Pepaxto retains EMA and MHRA approval. The report flags 34% year-over-year growth in clinical-trial registrations for peptide-based oncology compounds, with the majority targeting solid tumors previously considered peptide-resistant. Phase 2 ADC peptide-linker data released in early 2026 shows tumor-specific payload delivery rates above 85% — nearly double the 2023 benchmark — driven by the proteolytic-stability work that lets linker peptides survive serum peptidase degradation long enough to reach solid tumors.
Pfizer announced that data from more than 40 company-sponsored, investigator-sponsored, and collaborative research abstracts will appear at ASCO 2026 in Chicago (May 29–June 2). The slate spans Pfizer's diverse oncology pipeline including peptide-drug conjugate programs, bispecific T-cell engagers, and antibody-drug conjugates. Combined with previously announced ASCO 2026 acceptances from Bicycle Therapeutics, BriaCell, Greenwich LifeSciences, BioVaxys, and Immutep, the meeting is shaping up as the most peptide-and-immuno-conjugate-heavy ASCO in recent memory — building on the foundation laid at AACR 2026 in San Diego.
Mikhail Kolonin's group at UTHealth Houston published preclinical data showing BLMP6, a peptide identified through AI-guided modeling, selectively binds fibulin-4 — a protein highly expressed on metastatic triple-negative breast cancer cells — and not on noninvasive breast cancer or normal breast tissue. A BLMP6 conjugate carrying monomethyl auristatin E suppressed metastasis and improved survival in mouse models, and BLMP6-based fluorescent imaging probes successfully detected metastatic lesions. The paper, published in Molecular Therapy Oncology, identifies fibulin-4 as a new theranostic target.
A Nature paper from Liskiewicz, DiMarchi, Tschöp, Müller and colleagues introduces a unimolecular peptide-drug conjugate that combines a GLP-1R/GIPR co-agonist peptide with the pan-PPAR (α/γ/δ) agonist lanifibranor via a pH-sensitive linker. After receptor-mediated internalization, the linker cleaves and lanifibranor escapes to the nucleus to activate PPARs while the peptide moiety drives GLP-1R/GIPR signaling at the membrane. In obese, diabetic mice the conjugate produced greater weight loss and insulin sensitization than equimolar dosing of the unconjugated peptide and lanifibranor, without the typical PPAR-related cardiac and weight-gain safety signals.
Avacta Therapeutics presented April 21 data at AACR 2026 showing its FAP-enabled peptide-drug conjugate AVA6103, which delivers exatecan via the pre|CISION® platform, achieved a Tumor Selectivity Index three times higher than marketed ADC Enhertu in preclinical models, with tumor Cmax more than one log higher. AVA6103 entered the Phase 1 FOCUS-01 trial (NCT07454642) in March 2026 with initial clinical readout expected later this year.
A new market landscape report published April 21 projects the global peptide drug conjugate market will exceed $1.5 billion by 2031, with >14% CAGR and coverage of more than 50 peptide conjugates currently in clinical development. Commercial PDC benchmarks include Novartis's Lutathera and Pluvicto and Bicycle Therapeutics' nuzefatide pevedotin, with earlier-stage pipelines from Zymeworks, Bicycle, PeptiDream, and others.
Bicycle's EphA2-targeting bicyclic peptide-drug conjugate nuzefatide pevedotin (BT8009) at 6.5 mg/m² Q2W plus nivolumab achieved 40% confirmed ORR (4/10) in metastatic urothelial patients who had progressed on checkpoint inhibitors, and 100% (3/3) in MMAE-naive EphA2+ patients. No Grade ≥3 treatment-related adverse events of clinical interest. Presented at AACR 2026 on April 20.